In vivo biodistribution of nanoparticles

Nanomedicine

Volumn 6, Issue 5, 2011, Pages 815-835

  Almeida, Joao Paulo Mattos ^a   Chen, Allen L ^a   Foster, Aaron ^b   Drezek, Rebekah ^a  

^a Rice University   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

biodistribution; gold nanoparticle; iron oxide; nanoparticle; nanotechnology; quantum dot; toxicity

Indexed keywords

CETRIMIDE; DEXTRAN; GOLD NANOPARTICLE; MACROGOL; NANOPARTICLE; OLEIC ACID; POLOXAMER; POLYLYSINE; QUANTUM DOT; SILANE; STARCH; SUCCINIC ACID; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ADAPTIVE IMMUNITY; BIODEGRADATION; CIRCULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTOXICATION; HUMAN; HYDRODYNAMICS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

ANIMALS; FERRIC COMPOUNDS; GOLD; HUMANS; NANOPARTICLES; PARTICLE SIZE; TISSUE DISTRIBUTION;

EID: 79960946877     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.79     Document Type: Review

References (116)

1. Agasti SS, Rana S, Park MH, Kim CK, You CC, Rotello VM. Nanoparticles for detection and diagnosis. Adv. Drug Deliv. Rev. 62(3), 316-328 (2010).
2. Kennedy LC, Bickford LR, Lewinski NA et al. A new era for cancer treatment: gold-nanoparticle-mediated thermal therapies. Small 7(2), 169-183 (2011).
3. Kosaka N, McCann TE, Mitsunaga M, Choyke PL, Kobayashi H. Real-time optical imaging using quantum dot and related nanocrystals. Nanomedicine (Lond.) 5(5), 765-776 (2010).
4. Veiseh O, Gunn JW, Zhang MQ. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev. 62(3), 284-304 (2010).
5. Laurent S, Boutry S, Mahieu I, Vander Elst L, Muller RN. Iron oxide based MR contrast agents: from chemistry to cell labeling. Curr. Med. Chem. 16(35), 4712-4727 (2009).
6. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1(3), 297-315 (2006).
7. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995-4021 (2005). (Pubitemid 40044762)
8. Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307(5709), 538-544 (2005). (Pubitemid 40165671)
9. Zolnik BS, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv. Drug Deliv. Rev. 61(6), 422-427 (2009).
10. Li MG, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 4(11), 6303-6317 (2010).
11. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5(4), 505-515 (2008).
12. Choi HS, Frangioni JV. Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol. Imaging 9(6), 291-310 (2010).
13. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2(1), 99-112 (2010).
14. Henrikson RC, Kaye GI, Mazurkiewicz JE. NMS Histology. Lippencott Williams & Wilkins, Baltimore, ML, USA (1997).
15. Chrastina A, Schnitzer JE. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3(4), 421-437 (2011).
16. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin. Drug Deliv. 8(3), 343-357 (2011).
17. Lacerda SHD, Park JJ, Meuse C et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4(1), 365-379 (2010).
18. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61(6), 428-437 (2009).
19. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nature Nanotechnology 2(8), 469-478 (2007). (Pubitemid 47220069)
20. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006). (Pubitemid 41773257)
21. Guyton AC, Hall JE. Textbook of Medical Physiology. Elsevier, PA, USA (2006).
22. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008).
23. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.) 3(5), 703-717 (2008).
24. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001). (Pubitemid 32476118)
25. Villaraza AJL, Bumb A, Brechbiel MW. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem. Rev. 110(5), 2921-2959 (2010).
26. Laurent S, Forge D, Port M et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108(6), 2064-2110 (2008).
27. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomedicine (Lond.) 2(1), 23-39 (2007). (Pubitemid 46845774)
28. Vargas ER, Chen JW. Magnetic resonance imaging agents. In:Molecular Imaging: Principles and Practice. Weissleder R, Ross BD, Rehemtulla A, Gambhir SS (Eds).People's Medical Publishing House-USA, Shelton, CT, USA (2010).
29. Weissleder R, Bogdanov A, Neuwelt EA, Papisov M. Long-circulating iron-oxides for MR-imaging. Adv. Drug Deliv. Rev. 16(2-3), 321-334 (1995).
30. Chan DCF, Kirpotin DB, Bunn PA. Synthesis and evaluation of colloidal magnetic iron-oxides for the site-specific radiofrequency-induced hyperthermia of cancer. J. Magn. Magn. Mater. 122(1-3), 374-378 (1993).
31. Zhang GD, Liao YF, Baker I. Surface engineering of core/shell iron/iron oxide nanoparticles from microemulsions for hyperthermia. Mater. Sci. Eng. C Mater. Biol. Appl. 30(1), 92-97 (2010).
32. Frank JA, Miller BR, Arbab AS et al. Clinically applicable labeling of mammalian and stem cells by combining; superparamagnetic iron oxides and transfection agents. Radiology 228(2), 480-487 (2003). (Pubitemid 36910091)
33. Foy SP, Manthe RL, Foy ST, Dimitrijevic S, Krishnamurthy N, Labhasetwar V. Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors. ACS Nano 4(9), 5217-5224 (2010).
34. Liu HL, Hua MY, Yang HW et al. Magnetic resonance monitoring of focused ultrasound/ magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc. Natl Acad. Sci. USA 107(34), 15205-15210 (2010).
35. Bourrinet P, Bengele HH, Bonnemain B et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest. Radiol. 41(3), 313-324 (2006). (Pubitemid 44406193)
36. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur. Radiol. 13(6), 1266-1276 (2003). (Pubitemid 36790627)
37. Soenen SJH, De Cuyper M. Assessing iron oxide nanoparticle toxicity in vitro: current status and future prospects. Nanomedicine (Lond.) 5(8), 1261-1275 (2010).
38. Weissleder R, Stark DD, Engelstad BL et al. Superparamagnetic iron-oxide: pharmacokinetics and toxicity. Am. J. Roentgenol. 152(1), 167-173 (1989).
39. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J. Microencapsul. 13(3), 245-255 (1996). (Pubitemid 26149536)
40. Papisov MI, Bogdanov A, Schaffer B et al. Colloidal magnetic-resonance contrast agents: effect of particle surface on biodistribution. J. Magn. Magn. Mater. 122(1-3), 383-386 (1993).
41. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol. Pharm. 5(2), 316-327 (2008). (Pubitemid 351579134)
42. Chen HW, Wang LY, Yeh J et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-P g MPS copolymer coating. Biomaterials 31(20), 5397-5407 (2010).
43. Cole AJ, David AE, Wang J, Galbán CJ, Hill HL, Yang VC. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials 32(8), 2183-2193 (2011).
44. Larsen EKU, Nielsen T, Wittenborn T et al. Size-dependent accumulation of PEGylated silane-coated magnetic iron oxide nanoparticles in murine tumors. ACS Nano 3(7), 1947-1951 (2009).
45. Sun CR, Du K, Fang C et al. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo. ACS Nano 4(4), 2402-2410 (2010).
46. Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar V. Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials 30(35), 6748-6756 (2009).
47. Yu WW, Falkner JC, Yavuz CT, Colvin VL. Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem. Comm. (20), 2306-2307 (2004). (Pubitemid 39545903)
48. Yu WW, Chang E, Falkner JC et al. Forming biocompatible and nonaggregated nanocrystals in water using amphiphilic polymers. J. Am. Chem. Soc. 129(10), 2871-2879 (2007). (Pubitemid 46417963)
49. Chen HW, Wu XY, Duan HW et al. Biocompatible polysiloxane-containing diblock copolymer PEO-b-P g MPS for coating magnetic nanoparticles. ACS Appl. Mater. Interfaces 1(10), 2134-2140 (2009).
50. Briley-Saebo K, Bjornerud A, Grant D, Ahlstrom H, Berg T, Kindberg GM. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res. 316(3), 315-323 (2004). (Pubitemid 38823998)
51. Briley-Saebo K, Hustvedt SA, Haldorsen A, Bjornerud A. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent. J. Magn. Res. Imaging20(4), 622-631 (2004). (Pubitemid 39313738)
52. Levy M, Lagarde F, Maraloiu VA et al. Degradability of superparamagnetic nanoparticles in a model of intracellular environment: follow-up of magnetic, structural and chemical properties. Nanotechnology 21(39), 11 (2010).
53. Lawaczeck R, Bauer H, Frenzel T et al. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting - pre-clinical profile of SH U555A. Acta Radiologica, 38(4), 584-597 (1997).
54. Levy M, Luciani N, Alloyeau D et al. Long term in vivo biotransformation of iron oxide nanoparticles. Biomaterials 32, 3988-3999 (2011).
55. Lee MJE, Veiseh O, Bhattarai N et al. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. Plos ONE 5(3), 8 (2010).
56. Chertok B, Cole AJ, David AE, Yang VC. Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles. Mol. Pharm. 7(2), 375-385 (2010).
57. Alkilany AM, Murphy CJ. Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J. Nanopart. Res.12(7), 2313-2333 (2010).
58. Arvizo R, Bhattacharya R, Mukherjee P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin. Drug Deliv. 7(6), 753-763 (2010).
59. Huang XH, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostic and therapy. Nanomedicine (Lond.) 2(5), 681-693 (2007). (Pubitemid 350268247)
60. Jain PK, Lee KS, El-Sayed IH, El-Sayed MA. Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine. J. Phys. Chem. B 110(14), 7238-7248 (2006).
61. Hirsch LR, Stafford RJ, Bankson JA et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl Acad. Sci. USA 100(23), 13549-13554 (2003). (Pubitemid 37444779)
62. Han G, Ghosh P, Rotello VM. Functionalized gold nanoparticles for drug delivery. Nanomedicine (Lond.) 2(1), 113-123 (2007). (Pubitemid 46845782)
63. Paciotti GF, Myer L, Weinreich D et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 11(3), 169-183 (2004). (Pubitemid 38720414)
64. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev. 40(3), 1647-1671 (2011).
65. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips A, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29(12), 1912-1919 (2008).
66. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf. B Biointerfaces 66(2), 274-280 (2008).
67. Hirn S, Semmler-Behnke M, Schleh C et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur. J. Pharm. Biopharm. 77(3), 407-416 (2011).
68. Sadauskas E, Danscher G, Stoltenberg M, Vogel U, Larsen A, Wallin H. Protracted elimination of gold nanoparticles from mouse liver. Nanomedicine 5(2), 162-169 (2009).
69. Balasubramanian SK, Jittiwat J, Manikandan J, Ong CN, Yu LE, Ong WY. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 31(8), 2034-2042 (2010).
70. Zhang GD, Yang Z, Lu W et al. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 30(10), 1928-1936 (2009).
71. Cho WS, Cho M, Jeong J et al. Size-dependent tissue kinetics of PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol. 245(1), 116-123 (2010).
72. Goel R, Shah N, Visaria R, Paciotti GF, Bischof JC. Biodistribution of TNF-a-coated gold nanoparticles in an in vivo model system. Nanomedicine (Lond.) 4(4), 401-410 (2009).
73. Niidome T, Yamagata M, Okamoto Y et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J. Control. Release 114(3), 343-347 (2006). (Pubitemid 44310822)
74. Arnida, Janát-Amsbury MM, Ray A, Peterson CM, Ghandehari H. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur. J. Pharm. Biopharm. 77(3), 417-423 (2011).
75. Sun YN, Wang CD, Zhang XM, Ren L, Tian XH. Shape dependence of gold nanoparticles on in vivo acute toxicological effects and biodistribution. J. Nanosci. Nanotechnol. 11(2), 1210-1216 (2011).
76. Lipka J, Semmler-Behnke M, Sperling RA et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 31(25), 6574-6581 (2010).
77. Johnston HJ, Semmler-Behnke M, Brown DM, Kreyling W, Tran L, Stone V. Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol. Appl. Pharmacol. 242(1), 66-78 (2010).
78. Semmler-Behnke M, Kreyling WG, Lipka J et al. Biodistribution of 1.4-and 18-nm gold particles in rats. Small 4(12), 2108-2111 (2008).
79. Chen YS, Hung YC, Liau I, Huang GS. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res. Lett. 4(8), 858-864 (2009).
80. Cho WS, Cho MJ, Jeong J et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol. 236(1), 16-24 (2009).
81. Terentyuk GS, Maslyakova GN, Suleymanova LV et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J. Biophotonics 2(5), 292-302 (2009).
82. Choi HS, Liu W, Misra P et al. Renal clearance of quantum dots. Nat. Biotechnol. 25(10), 1165-1170 (2007). (Pubitemid 47538116)
83. Smith AM, Duan HW, Mohs AM, Nie SM. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60(11), 1226-1240 (2008).
84. Gao XH, Cui YY, Levenson RM, Chung LWK, Nie SM. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22(8), 969-976 (2004). (Pubitemid 39014473)
85. Akerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc. Natl Acad. Sci. USA 99(20), 12617-12621 (2002).
86. Cai WB, Shin DW, Chen K et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6(4), 669-676 (2006).
87. Diagaradjane P, Orenstein-Cardona JM, Colon-Casasnovas NE et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin. Cancer Res. 14(3), 731-741 (2008). (Pubitemid 351231154)
88. Yang RH, Chang LW, Wu JP et al. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ. Health Perspect. 115(9), 1339-1343 (2007). (Pubitemid 47471259)
89. Chen Z, Chen H, Meng H et al. Bio-distribution and metabolic paths of silica coated CdSeS quantum dots. Toxicol. Appl. Pharmacol. 230(3), 364-371 (2008).
90. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconj. Chem. 15(1), 79-86 (2004). (Pubitemid 38165983)
91. Schipper ML, Cheng Z, Lee SW et al. MicroPET-based biodistribution of quantum dots in living mice. J. Nucl. Med. 48(9), 1511-1518 (2007). (Pubitemid 47397401)
92. Schipper ML, Iyer G, Koh AL et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 5(1), 126-134 (2009).
93. Choi HS, Ipe BI, Misra P, Lee JH, Bawendi MG, Frangioni JV. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett. 9(6), 2354-2359 (2009).
94. Fischer HC, Liu LC, Pang KS, Chan WCW. Pharmacokinetics of nanoscale quantum dots: in vivo distribution, sequestration, and clearance in the rat. Adv. Funct. Mater. 16(10), 1299-1305 (2006). (Pubitemid 44049451)
95. Yong KT, Roy I, Ding H, Bergey EJ, Prasad PN. Biocompatible near-infrared quantum dots as ultrasensitive probes for long-term in vivo imaging applications. Small 5(17), 1997-2004 (2009).
96. Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WCW. In vivo quantum-dot toxicity assessment. Small 6(1), 138-144 (2010).
97. Mancini MC, Kairdolf BA, Smith AM, Nie SM. Oxidative quenching and degradation of polymer-encapsulated quantum dots: new insights into the long-term fate and toxicity of nanocrystals in vivo. J. Am. Chem. Soc. 130(33), 10836 (2008).
98. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fateinside the cellular compartment: a microscopic overview. Langmuir 21(23), 10644-10654 (2005). (Pubitemid 41692144)
99. Ma JS, Kim WJ, Kim JJ et al. Gold nanoparticles attenuate LPS-induced NO production through the inhibition of NF-?B and IFN-β/STAT1 pathways in RAW264.7 cells. Nitric Oxide 23(3), 214-219 (2010).
100. Yen HJ, Hsu SH, Tsai CL. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small 5(13), 1553-1561 (2009).
101. Dobrovolskaia MA, Patri AK, Zheng J et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 5(2), 106-117 (2009).
102. Yeh CH, Hsiao JK, Wang JL, Sheu F. Immunological impact of magnetic nanoparticles (ferucarbotran) on murine peritoneal macrophages. J. Nanopart. Res.12(1), 151-160 (2010).
103. Villiers CL, Freitas H, Couderc R, Villiers MB, Marche PN. Analysis of the toxicity of gold nano particles on the immune system: Effect on dendritic cell functions. J. Nanopart. Res. 12(1), 55-60 (2010).
104. Moore A, Marecos E, Bogdanov Jr A, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214(2), 568-574 (2000). (Pubitemid 30077721)
105. Cubillos-Ruiz JR, Engle X, Scarlett UK et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J. Clin. Invest. 119(8), 2231-2244 (2009).
106. Cubillos-Ruiz JR, Hoopes J, Fiering S, Conejo-Garcia JR. Inflammatory and immune responses induced by nanomaterials: challenges and opportunities for future nanotherapies. Nanotechnology Perceptions 5(3), 195-203 (2009).
107. Park J, Estrada A, Schwartz JA et al. Intra-organ biodistribution of gold nanoparticles using intrinsic two-photon-induced photoluminescence. Lasers Surg. Med. 42(7), 630-639 (2010).
108. Hutter E, Boridy S, Labrecque S et al. Microglial response to gold nanoparticles. ACS Nano 4(5), 2595-2606 (2010).
109. Rehberg M, Praetner M, Leite CF et al. Quantum dots modulate leukocyte adhesion and transmigration depending on their surface modification. Nano Lett. 10(9), 3656-3664 (2010).
110. Hoshino A, Hanada S, Manabe N, Nakayama T, Yamamoto K. Immune response induced by fluorescent nanocrystal quantum dots in vitro and in vivo. IEEE Trans. Nanobioscience 8(1), 51-57 (2009).
111. 4 on immune function in normal ICR mice. Int. J. Nanomed. 5, 593-599 (2010).
112. Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 6(4), 523-529 (2010).
113. Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R. Perturbational profiling of nanomaterial biologic activity. Proc. Natl Acad. Sci. USA 105(21), 7387-7392 (2008). (Pubitemid 351830027)
114. Tropsha A, Golbraikh A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr. Pharm. Design 13(34), 3494-3504 (2007). (Pubitemid 350238939)
115. Fourches D, Pu DQY, Tassa C et al. Quantitative nanostructure-activity relationship modeling. ACS Nano 4(10), 5703-5712 (2010).
116. Espie P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB. Physiologically based pharmacokinetics (PBPK).Drug Metab. Rev. 41(3), 391-407 (2009).